11/15/2025
Now in : 2025 ACC Scientific Statement on the Management of in Adults With
Obesity drives risk for HF, CAD & , but targeted weight loss can change the game. Semaglutide & tirzepatide show promise in , but challenges remain. Clinicians must rethink how to diagnose, assess & manage obesity in HF.
🔗 Read the full statement here: https://bit.ly/43qdfRg